Dyadic International, Inc. (DYAI) News
Filter DYAI News Items
DYAI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest DYAI News From Around the Web
Below are the latest news stories about DYADIC INTERNATIONAL INC that investors may wish to consider to help them evaluate DYAI as an investment opportunity.
Dyadic Attends Investor Events in DecemberJUPITER, Fla., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be attending |
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine CandidatePrimary endpoint met Demonstrated safety and reactogenicity of DYAI-100 recombinant proteinC1-cell produced antigen was both safe and well-toleratedNo Serious Adverse Events reportedFinal Clinical Study Report available in the coming weeks JUPITER, Fla., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the grow |
Shareholders in Dyadic International (NASDAQ:DYAI) are in the red if they invested three years agoIf you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But... |
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in AfricaJUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today applauds the signing of an agreement between Dyadic’s African licens |
Dyadic International, Inc. (NASDAQ:DYAI) Q3 2023 Earnings Call TranscriptDyadic International, Inc. (NASDAQ:DYAI) Q3 2023 Earnings Call Transcript November 8, 2023 Dyadic International, Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. Operator: Good evening, and welcome to the Dyadic International’s Third Quarter 2023 Financial Results Conference Call. Currently all participants are in a listen-only mode. Following management’s prepared […] |
DYAI: Third Quarter UpdateBy John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) provided 3Q:23 operational and financial results in a press release on November 8, 2023, filed its Form 10-Q with the SEC and held a conference call with investors. Dyadic announced new collaborations with bYoRNA, INZYMES and a Department of Defense program for vaccines. Several other |
Dyadic International Inc (DYAI) Reports Decrease in Q3 Revenue and Net Loss Improvement ...Financial Highlights and Company Developments in Third Quarter 2023 |
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company ProgressReceived an upfront payment of $0.6 million in October for product development and licensing of our Dapibus™ platform for animal-free dairy enzyme products DYAI-100 Phase 1 clinical trial top-line results expected in December 2023 New research collaboration with Vaccine and Immunotherapy Center at Massachusetts General Hospital as part of US $5.88 million awards from the Department of Defense (“DoD”) New development and commercialization agreement with bYoRNA to develop cost-effective messenger |
Dyadic to Present at Industry Events in NovemberJUPITER, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be participa |
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023JUPITER, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that it will repor |